摩根大通将Relay Therapeutics的目标价下调至23美元，理由是每股收益为负和内幕交易。 JPMorgan lowers Relay Therapeutics' target price to $23, citing negative EPS and insider trading.

摩根大通（JPMorgan Chase & Co.）和其他几家公司下调了Relay Therapeutics（纳斯达克股票代码：RLAY）的目标价，摩根大通将其目标价从29.00美元下调至23.00美元。 JPMorgan Chase & Co. and several other firms have lowered Relay Therapeutics' (NASDAQ: RLAY) target prices, with JPM reducing its target from $29.00 to $23.00. 分析员预计本年度每股负收益,发现内部交易活动。 Analysts expect negative earnings per share for the current year and insider trading activity has been observed. 这些调整是继最近关于各种价格目标和评级的报告之后作出的。 These adjustments follow recent reports with various price objectives and ratings. 其他大型机构投资者也对其持有的Relay Therapeutics股票进行了变化. Large institutional investors have also made changes to their holdings of Relay Therapeutics shares.